**MINUTES**

**CPIC CONFERENCE CALL**

DATE: February 4, 2021

| TOPIC | DISCUSSION/ACTION | FOLLOW-UP |
| --- | --- | --- |
| Housekeeping announcements | Attendance will be taken by poll after each conference call. Members will receive an email with a doodle link after each call. Please enter your first and last name and check the box indicating you were in attendance. No action required if you were unable to make the conference call. | Kelly will send the poll link. |
| Member gene/drug guideline prioritization results | Based on a survey distributed to CPIC members, the top gene/drug pairs of interest for future guidelines include *CYP2D6/*antipsychotics, *CYP2D6*/beta-blockers, *UGT1A1*/anticancer drugs, *CYP2C19*/benzodiazepines, and *CYP2B6*/methadone. | Email Kelly (kelly.caudle@stjude.org) if you would like to nominate yourself or a colleague to be an author for the *CYP2D6*/beta-blocker guideline.  |
| CPIC and PharmGKB linked on ClinGen | ClinGen ([www.clinicalgenome.org](http://www.clinicalgenome.org)), an online resource that focuses on gene-disease associations, is now partnering with CPIC and PharmGKB to provide pharmacogenomic information through their website. You can now search for pharmacogenes on ClinGen and it will link to information curated from CPIC and PharmGKB. | Plans also exist to classify pharmacogenes as curated genes on ClinGen. |
| Allele function and phenotype assignment SOP changes  | The standard operating procedures (SOP) for assigning allele function and for translating diplotypes to phenotypes are in the process of being updated, partly in efforts to meet criteria for FDA recognition. This document describes procedures for expert selection and training; evidence collection and inclusion of alleles; assigning strength of evidence and allele function; summarizing the evidence; translating diplotypes to phenotypes; and re-evaluations and updates. Guideline authors will need to complete training related to the new SOP that includes an assessment, and there will be an expert attestation to document each author’s review and agreement with the assertions in the allele function evidence and diplotype to phenotype tables.  | Please respond to queries from Kelly or others on attestation and training. |